Created at	Source	Raw Value	Validated value
May 5, 2022, 11:30 p.m.	oms	Phase 2a PartChange from baseline in SARS-CoV-2 viral titer at each time pointPhase 2b PartTime-weighted average change in total score of 12 COVID-19 symptoms from Day 1 up to Day 6Change from baseline on Day 4 in SARS CoV-2 viral titerPhase 3 PartTime to resolution of COVID-19 symptomsTime to the first negative SARS CoV-2 viral titerPhase 2b/3 PartFor asymptomatic/only mild symptom SARS-CoV-2-infected participants:Proportion of participants with occurrence/worsening of COVID-19 symptomsTime to first confirmation of negative SARS CoV-2 viral titer	Phase 2a PartChange from baseline in SARS-CoV-2 viral titer at each time pointPhase 2b PartTime-weighted average change in total score of 12 COVID-19 symptoms from Day 1 up to Day 6Change from baseline on Day 4 in SARS CoV-2 viral titerPhase 3 PartTime to resolution of COVID-19 symptomsTime to the first negative SARS CoV-2 viral titerPhase 2b/3 PartFor asymptomatic/only mild symptom SARS-CoV-2-infected participants:Proportion of participants with occurrence/worsening of COVID-19 symptomsTime to first confirmation of negative SARS CoV-2 viral titer
March 4, 2022, 2 p.m.	oms	Phase 2a PartCommon for mild/moderate and asymptomatic SARS-CoV-2-infected participants:Change from baseline in SARS-CoV-2 viral titer at each time pointPhase 2b/3 PartFor mild/moderate SARS-CoV-2-infected participants:Time to improvement of COVID-19 symptomsFor asymptomatic/only mild symptom SARS-CoV-2-infected participants:Proportion of participants with occurrence/worsening of COVID-19 symptomsCommon for mild/moderate and asymptomatic/only mild symptom SARS-CoV-2-infected participants:Time to first confirmation of negative SARS CoV-2 viral titer	Phase 2a PartCommon for mild/moderate and asymptomatic SARS-CoV-2-infected participants:Change from baseline in SARS-CoV-2 viral titer at each time pointPhase 2b/3 PartFor mild/moderate SARS-CoV-2-infected participants:Time to improvement of COVID-19 symptomsFor asymptomatic/only mild symptom SARS-CoV-2-infected participants:Proportion of participants with occurrence/worsening of COVID-19 symptomsCommon for mild/moderate and asymptomatic/only mild symptom SARS-CoV-2-infected participants:Time to first confirmation of negative SARS CoV-2 viral titer
Dec. 30, 2021, 7:30 p.m.	oms	Phase 2a PartCommon for mild/moderate and asymptomatic SARS-CoV-2-infected participants:Change from baseline in SARS-CoV-2 viral titer at each time pointPhase 2b/3 PartFor mild/moderate SARS-CoV-2-infected participants:Time to improvement of COVID-19 symptomsFor asymptomatic SARS-CoV-2-infected participants:Proportion of participants with occurrence of COVID-19 symptomsCommon for mild/moderate and asymptomatic SARS-CoV-2-infected participants:Time to first confirmation of negative SARS CoV-2 viral titer	Phase 2a PartCommon for mild/moderate and asymptomatic SARS-CoV-2-infected participants:Change from baseline in SARS-CoV-2 viral titer at each time pointPhase 2b/3 PartFor mild/moderate SARS-CoV-2-infected participants:Time to improvement of COVID-19 symptomsFor asymptomatic SARS-CoV-2-infected participants:Proportion of participants with occurrence of COVID-19 symptomsCommon for mild/moderate and asymptomatic SARS-CoV-2-infected participants:Time to first confirmation of negative SARS CoV-2 viral titer
Oct. 21, 2021, 10 a.m.	oms	Phase 2a PartCommon for mild and asymptomatic SARS-CoV-2-infected participants:Change from baseline in SARS-CoV-2 viral titer at each time pointPhase 2b/3 PartFor mild SARS-CoV-2-infected participants:Time to improvement of COVID-19 symptomsFor asymptomatic SARS-CoV-2-infected participants:Proportion of participants with occurrence of COVID-19 symptomsCommon for mild and asymptomatic SARS-CoV-2-infected participants:Time to first confirmation of negative SARS CoV-2 viral titer	Phase 2a PartCommon for mild and asymptomatic SARS-CoV-2-infected participants:Change from baseline in SARS-CoV-2 viral titer at each time pointPhase 2b/3 PartFor mild SARS-CoV-2-infected participants:Time to improvement of COVID-19 symptomsFor asymptomatic SARS-CoV-2-infected participants:Proportion of participants with occurrence of COVID-19 symptomsCommon for mild and asymptomatic SARS-CoV-2-infected participants:Time to first confirmation of negative SARS CoV-2 viral titer